drugset / Trial / NCT06139536
Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BAT4706 Injection Combined With BAT1308 Injection in Patients With Advanced Solid Tumors.
Timeline
- Start
- 2024-03-06
- Primary completion
- 2025-12
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT1308 | Monoclonal antibody | 300 mg | Intravenous |
| Subject | BAT4706 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | BAT4706 | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | BAT4706 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | BAT4706 | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | BAT4706 | Monoclonal antibody | 10 mg/kg | Intravenous |